On October 27, 2016, biotech experts and industry professionals will converge on London to discuss the sector’s outlook.
On October 27, 2016, biotech experts and industry professionals will converge on London. Their purpose? To discuss R&D challenges from a UK perspective, as well as consider how the biotech sector might respond to Brexit.
FierceBiotech is hosting the event, which takes place at the Royal Society of Medicine. The conference consists of two panels and a fireside chat, where topics up for debate will include the role of NICE in drug pricing, current industry trends and the anticipated impact of Brexit on Britain’s biotech sector.
What is England’s influence on drug-pricing worldwide?
How can the country attract biotech investment post-Brexit?
Why is the clinical trial process changing … and what might it look like in the future?
These questions, and others like them, will be considered by an esteemed group of industry experts. Speakers and panelists include Joanne Hulbert, a director of global regulatory affairs at PRA Health Sciences; Divya Chadha Manek, the Head of Commercial Business Development at the NIHR Clinical Research Network; and Dr. Jonathan Flelden, Director of Specialized Commissioning and Deputy Nation Medical Director at NHS England.
Register now for the event. But if you’re not lucky enough to attend? Never fear. We’ll be live tweeting the conference, so stay tuned to @INN_LifeScience for real-time updates.
And make sure to check back here following the event—you can bet we’ll be covering all of the major takeaways in detail!
Don’t forget to follow us @INN_LifeScience for conference updates.
Securities Disclosure: I, Chelsea Pratt, hold no direct investment interest in any company mentioned in this article.